Advanced Filters
noise

Intermittent Explosive Disorder Clinical Trials

A listing of Intermittent Explosive Disorder medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 75 clinical trials
D Daiga Santare, MD, PhD

Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach

The study is aimed to determine the potential of volatile marker testing for gastric cancer screening. The study will be addressing the role of confounding factors, including lifestyle factors, diet, smoking as well as addressing the potential role of microbiota in the composition of exhaled volatile markers.

18 years of age All Phase N/A
Y Yongquan Shi, Ph.D

Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment

This study aims at evaluating efficacy and safety of Saccharomyces boulardii combined with bismuth-containing quadruple Therapy versus bismuth-containing quadruple Therapy(bismuthesomeprazoletetracycline and furazolidone) in H. pylori rescue therapy. It is hypothesized that Saccharomyces boulardii combined with bismuth-containing quadruple Therapy is superior to bismuth-containing quadruple Therapy. Patients with confirmed failure of H. …

18 - 75 years of age All Phase 4
G Guihe Wang

Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection

This is a prospective study designed to compare the performance of fecal H. pylori gastric cancer susceptibility analysis and the gastric cancer risk questionnaire for the early detection of gastric cancer. The primary objective is to assess whether each method, individually or in combination, can facilitate earlier diagnosis of gastric …

40 years of age All Phase N/A
G Guihe Wang

An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori

This study is intended to be a prospective observational cohort study. The incidence of gastric cancer and progression of gastric precancerous lesions will be compared between groups through prospective follow-up of a population with baseline negative gastric endoscopy, harboring high-risk Hp SNP subtypes and non-high-risk subtypes.

40 years of age All Phase N/A
R Robert J Huang, MD

The GAstric Precancerous Conditions Study

Gastric cancer afflicts 27,000 Americans annually and carries a dismal prognosis. One reason for poor outcomes is late diagnosis, as the majority of gastric cancers in the United States are diagnosed at a relatively advanced stage where curative resection is unlikely. Gastric precursors (such as atrophic gastritis and intestinal metaplasia) …

35 - 84 years of age All Phase N/A
Y Ying Han

Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication

The goal of this clinical trial is to compare eradication rates of Helicobacter pylori in patients aged 18-70 years with first infection. The main questions it aims to answer are: Main indicators: the eradication rate of Helicobacter pylori for eradication. Secondary indicators: symptomatic relief rate at 2 weeks after treatment …

18 - 70 years of age All Phase 4
M Michele B. Ryan, MS

H. Pylori Eradication With Argon Plasma During Endoscopy

The objective of the study is to investigate the efficacy and safety of an argon plasma-based therapy - HEAPE - in treating H. pylori infections during endoscopic procedures. By filling the stomach with sodium chloride solution that is treated with APC (PAL), the Investigators hypothesize a significant reduction in H. …

18 years of age All Phase N/A

Efficacy of Vonoprazan Based Dual and Triple Therapy for Patient With Helicobacter Pylori Infection

This study aims to assess Efficacy of vonoprazan based dual and triple therapy for naïve patient with Helicopacter Pylori infection in Sohag Government .

19 years of age All Phase N/A
J Jun-Hyung Cho, M.D.

Tegoprazan- Versus PPI-based H. Pylori Eradication

In 2015, vonoprazan, a potassium-competitive blocker (P-CAB), was launched in Japan and used as an alternative for proton pump inhibitors (PPIs) for eradicating Helicobacter pylori. In recent studies, vonoprazan-based triple therapy significantly increased the eradication rate from 72.8% to 87.9%, compared to PPI treatment group. Accordingly, the Japanese Helicobacter treatment …

20 - 80 years of age All Phase N/A

Recurrence of H Pylori : Incidence and Influential Factors.

This study aims to determine recurrence rates, identify influential factors, investigate key factors that contribute to recurrence, evaluate treatment effectiveness and to assess the efficacy of different eradication regimens and their role in reducing recurrence.

18 - 75 years of age All Phase N/A

Simplify language using AI